Chelsea set to face Barca and Spurs to get Valencia, say CL draw calculations

first_imgCHELSEA are most likely to face Barcelona in the Champions League last 16, according to the calculations.The Blues ended their group stage campaign with a 2-1 win over Lille  and 11 points – but still managed to only finish second in Group G.4 The permutations for the Champions League last 16 draw4 Chelsea are most likely to face Barcelona in the Champions League last 16Credit: ReutersFrank Lampard’s side must now face a team who finished top of their group.And the calculations say Chelsea have a 23.28 per cent shot of landing the La Liga champions – the highest chance of any team to face any other team in the entire draw.The Stamford Bridge side cannot face Liverpool or Manchester City – who topped their groups – as rules forbid teams from the same nation being drawn together at this stage of the competition.Chelsea also can’t face Valencia, as they were in the same group together – giving them just five options in the last 16.ACCA WITH LADBROKES Pick up a whole load of acca features to help you land the big oneAlong with Barcelona, they could face Juventus (21.67 per cent), Bayern Munich (18.9 per cent), Paris Saint-Germain (18.18 per cent) or Red Bull Leipzig (17.98 per cent) – ensuring they have a tricky route to the quarter-finals.Meanwhile, Tottenham are most likely to land Valencia in the upcoming draw with a 22.61 per cent shot.Barcelona (22 per cent), Juventus (20.72 per cent), RB Leipzig (17.34 per cent) and PSG (17.33 per cent) complete their list.Amongst the other English teams, Premier League-leaders Liverpool are most likely to face Atletico Madrid – a 22.4 per cent likelihood.4MORE CHELSEA STORIESLive Blogblues newsChelsea news LIVE – Latest updates from Stamford BridgeGossipGOING DUTCHChelsea ‘to grab Mbuyamba on free deal’ with defender set to leave BarcelonaCOURT ORDERKante ‘ordered to appear in court’ in £3.4m legal battle with former agentBRIDGE OF SIGHSChelsea stars ‘bored’ and Hazard suffered under Sarri, says ex-No2 ZolaGossipBERN IT UPMan Utd, Arsenal and Chelsea on alert after Bernardeschi reveals Prem plansLive BlogBLUES NEWSChelsea news LIVE: Latest updates and transfer gossip from Stamford BridgeGossipSAMU’LL DOChelsea turn attention to Villarreal’s Chukwueze as United edge closer to SanchoJESUS HEISTChelsea talks with Jesus Corona confirmed as agent reveals ace open to transferGossipLIAN HEARTWillian wanted by PSG on a free with Arsenal in hunt ahead of deal running outPicturedBUL OVEREx-Chelsea man Bulka wrecks £200k Lamborghini in horror crash in Poland lockdownThe rampant Reds could also draw Real Madrid (21.58 per cent) Borussia Dortmund (20.62 per cent), Atalanta (18.44 per cent) or Lyon (16.97 per cent).Meanwhile, Man City are most likely to face Atleti too, also with a 22.4 per cent shot.Their numbers are identical to Liverpool for Real, Dortmund and Lyon – but they’re an 18.44 per cent shot to come up against Napoli.4Neymar wanted by Chelsea, Manchester City and Liverpool as trio join transfer battle for wantaway PSG starlast_img read more

Drug Company Teaming With Yale to Share Trial Data

first_imgJohnson & Johnson announced an unusual partnership today with Yale University, in which it will share raw data from many of its clinical trials. The Yale University Open Data Access Project (aptly nicknamed YODA) will “review requests from investigators and physicians seeking access to anonymized clinical trials data from Janssen, the pharmaceutical companies of Johnson & Johnson,” the company wrote in a press release. YODA’s team will then decide which researchers can access the information for their own studies.The announcement prompted a small explosion of news stories. Forbes wrote that “initially, this will only include products from the drug division, but it will expand to include devices and consumer products.” Janssen’s pharmaceutical products stretch the gamut, including pills for acid reflux, schizophrenia, pain, and birth control, among others. The data to be shared with YODA go well beyond study design and results, and include de-identified information on every volunteer. YODA is led by Harlan Krumholz, a cardiologist who has long pressed for more data access in clinical research. (In 2010, Forbes named him “The Most Powerful Doctor You Never Heard Of.”)Johnson & Johnson, of course, will get to decide what it sends over to New Haven, although it’s pledging broad disclosure. That’s somewhat in contrast with a controversy brewing in Europe, where drug regulators are hoping to release the same kind of raw data submitted to it by pharmaceutical companies. That effort has been met with pushback and lawsuits. But it is part of a broader shift in both the United States and Europe, where researchers and some regulators are increasingly frustrated by the secrecy surrounding many drug trials, and want to get the information out in the open.Sign up for our daily newsletterGet more great content like this delivered right to you!Country *AfghanistanAland IslandsAlbaniaAlgeriaAndorraAngolaAnguillaAntarcticaAntigua and BarbudaArgentinaArmeniaArubaAustraliaAustriaAzerbaijanBahamasBahrainBangladeshBarbadosBelarusBelgiumBelizeBeninBermudaBhutanBolivia, Plurinational State ofBonaire, Sint Eustatius and SabaBosnia and HerzegovinaBotswanaBouvet IslandBrazilBritish Indian Ocean TerritoryBrunei DarussalamBulgariaBurkina FasoBurundiCambodiaCameroonCanadaCape VerdeCayman IslandsCentral African RepublicChadChileChinaChristmas IslandCocos (Keeling) IslandsColombiaComorosCongoCongo, The Democratic Republic of theCook IslandsCosta RicaCote D’IvoireCroatiaCubaCuraçaoCyprusCzech RepublicDenmarkDjiboutiDominicaDominican RepublicEcuadorEgyptEl SalvadorEquatorial GuineaEritreaEstoniaEthiopiaFalkland Islands (Malvinas)Faroe IslandsFijiFinlandFranceFrench GuianaFrench PolynesiaFrench Southern TerritoriesGabonGambiaGeorgiaGermanyGhanaGibraltarGreeceGreenlandGrenadaGuadeloupeGuatemalaGuernseyGuineaGuinea-BissauGuyanaHaitiHeard Island and Mcdonald IslandsHoly See (Vatican City State)HondurasHong KongHungaryIcelandIndiaIndonesiaIran, Islamic Republic ofIraqIrelandIsle of ManIsraelItalyJamaicaJapanJerseyJordanKazakhstanKenyaKiribatiKorea, Democratic People’s Republic ofKorea, Republic ofKuwaitKyrgyzstanLao People’s Democratic RepublicLatviaLebanonLesothoLiberiaLibyan Arab JamahiriyaLiechtensteinLithuaniaLuxembourgMacaoMacedonia, The Former Yugoslav Republic ofMadagascarMalawiMalaysiaMaldivesMaliMaltaMartiniqueMauritaniaMauritiusMayotteMexicoMoldova, Republic ofMonacoMongoliaMontenegroMontserratMoroccoMozambiqueMyanmarNamibiaNauruNepalNetherlandsNew CaledoniaNew ZealandNicaraguaNigerNigeriaNiueNorfolk IslandNorwayOmanPakistanPalestinianPanamaPapua New GuineaParaguayPeruPhilippinesPitcairnPolandPortugalQatarReunionRomaniaRussian FederationRWANDASaint Barthélemy Saint Helena, Ascension and Tristan da CunhaSaint Kitts and NevisSaint LuciaSaint Martin (French part)Saint Pierre and MiquelonSaint Vincent and the GrenadinesSamoaSan MarinoSao Tome and PrincipeSaudi ArabiaSenegalSerbiaSeychellesSierra LeoneSingaporeSint Maarten (Dutch part)SlovakiaSloveniaSolomon IslandsSomaliaSouth AfricaSouth Georgia and the South Sandwich IslandsSouth SudanSpainSri LankaSudanSurinameSvalbard and Jan MayenSwazilandSwedenSwitzerlandSyrian Arab RepublicTaiwanTajikistanTanzania, United Republic ofThailandTimor-LesteTogoTokelauTongaTrinidad and TobagoTunisiaTurkeyTurkmenistanTurks and Caicos IslandsTuvaluUgandaUkraineUnited Arab EmiratesUnited KingdomUnited StatesUruguayUzbekistanVanuatuVenezuela, Bolivarian Republic ofVietnamVirgin Islands, BritishWallis and FutunaWestern SaharaYemenZambiaZimbabweI also wish to receive emails from AAAS/Science and Science advertisers, including information on products, services and special offers which may include but are not limited to news, careers information & upcoming events.Required fields are included by an asterisk(*)last_img read more